Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Wedbush lifted their Q2 2019 earnings estimates for Alexion Pharmaceuticals in a note issued to investors on Tuesday, July 16th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings per share of $2.08 for the quarter, up from their prior estimate of $2.01. Wedbush currently has a “Outperform” rating and a $173.00 target price on the stock. Wedbush also issued estimates for Alexion Pharmaceuticals’ Q3 2019 earnings at $2.13 EPS, Q4 2019 earnings at $2.33 EPS and FY2019 earnings at $8.73 EPS.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.40. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the business posted $1.68 earnings per share. The company’s revenue was up 22.5% on a year-over-year basis.

A number of other equities analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Hammerson from a “hold” rating to a “sell” rating in a research note on Friday, May 24th. Goldman Sachs Group raised shares of Lenovo Group from a “neutral” rating to a “buy” rating in a research note on Thursday, May 23rd. They noted that the move was a valuation call. Royal Bank of Canada decreased their price target on shares of Gildan Activewear from $34.00 to $33.00 and set a “sector perform” rating for the company in a research note on Wednesday, March 27th. BidaskClub downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, Guggenheim reissued a “neutral” rating and issued a $325.00 price target on shares of Biogen in a research note on Thursday, March 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $161.06.

ALXN stock opened at $123.26 on Wednesday. Alexion Pharmaceuticals has a 1 year low of $92.56 and a 1 year high of $141.86. The company has a market capitalization of $27.54 billion, a P/E ratio of 17.39, a P/E/G ratio of 0.92 and a beta of 1.64. The business has a 50-day moving average of $123.54. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25.

In related news, insider Aradhana Sarin sold 578 shares of Alexion Pharmaceuticals stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $132.00, for a total transaction of $76,296.00. Following the completion of the transaction, the insider now directly owns 30,201 shares of the company’s stock, valued at approximately $3,986,532. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $132.78, for a total transaction of $597,510.00. Following the transaction, the executive vice president now directly owns 29,627 shares of the company’s stock, valued at $3,933,873.06. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 428,567 shares of company stock valued at $53,420,869. 4.08% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its stake in shares of Alexion Pharmaceuticals by 17.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 635,679 shares of the biopharmaceutical company’s stock worth $61,893,000 after purchasing an additional 95,895 shares during the period. Stifel Financial Corp increased its stake in shares of Alexion Pharmaceuticals by 0.8% during the fourth quarter. Stifel Financial Corp now owns 67,815 shares of the biopharmaceutical company’s stock worth $6,677,000 after purchasing an additional 520 shares during the period. Captrust Financial Advisors bought a new position in shares of Alexion Pharmaceuticals during the fourth quarter worth approximately $31,000. Geode Capital Management LLC increased its stake in shares of Alexion Pharmaceuticals by 7.5% during the fourth quarter. Geode Capital Management LLC now owns 2,681,909 shares of the biopharmaceutical company’s stock worth $260,616,000 after purchasing an additional 187,834 shares during the period. Finally, BOKF NA increased its stake in shares of Alexion Pharmaceuticals by 13.1% during the fourth quarter. BOKF NA now owns 4,630 shares of the biopharmaceutical company’s stock worth $450,000 after purchasing an additional 536 shares during the period. 94.74% of the stock is owned by hedge funds and other institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: What is a resistance level?

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.